Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 289

1.

Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).

Waksman R, Bertrand O, Driesman M, Gruberg L, Rossi J, Mehta S, Swymelar S, Dvir D, Xue Z, Torguson R.

J Interv Cardiol. 2013 Apr;26(2):107-13. doi: 10.1111/joic.12005. Epub 2012 Dec 13.

PMID:
23240743
2.
3.

Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.

Steinberg DH, Shah P, Kinnaird T, Pinto Slottow TL, Roy PK, Okabe T, Bonello L, de Labriolle A, Smith KA, Torguson R, Xue Z, Suddath WO, Kent KM, Satler LF, Pichard AD, Lindsay J, Waksman R.

Am J Cardiol. 2008 Jul 15;102(2):160-4. doi: 10.1016/j.amjcard.2008.03.030. Epub 2008 May 28.

PMID:
18602514
6.

Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors.

Abtahian F, Waldo S, Jang IK.

Catheter Cardiovasc Interv. 2015 Sep;86(3):390-6. doi: 10.1002/ccd.25911. Epub 2015 Mar 30.

PMID:
25753749
7.

Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).

Patti G, Pasceri V, D'Antonio L, D'Ambrosio A, Macrì M, Dicuonzo G, Colonna G, Montinaro A, Di Sciascio G.

Am J Cardiol. 2012 Aug 15;110(4):478-84. doi: 10.1016/j.amjcard.2012.04.017. Epub 2012 May 12.

PMID:
22583760
8.

Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.

Feldman DN, Minutello RM, Bergman G, Moussa I, Wong SC.

Catheter Cardiovasc Interv. 2010 Oct 1;76(4):513-24. doi: 10.1002/ccd.22546.

PMID:
20882655
9.

Safety of bivalirudin in percutaneous coronary intervention following thrombolytic therapy.

Sardi GL, Lindsay J, Waksman R.

Catheter Cardiovasc Interv. 2013 Oct 1;82(4):614-20. doi: 10.1002/ccd.24478. Epub 2013 Jul 4.

PMID:
22581418
10.

Validation of long-term benefits of bivalirudin versus unfractionated heparin in routine clinical practice after percutaneous coronary intervention.

Vidi VD, Matheny ME, Agarwal V, Arora N, Donnelly S, Bangalore S, Resnic FS.

Am J Cardiol. 2010 Nov 1;106(9):1234-40. doi: 10.1016/j.amjcard.2010.06.047. Epub 2010 Sep 9.

11.

Bivalirudin during primary PCI in acute myocardial infarction.

Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators.

N Engl J Med. 2008 May 22;358(21):2218-30. doi: 10.1056/NEJMoa0708191.

12.

Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty.

Shah A, Feldman DN.

Vasc Health Risk Manag. 2012;8:115-23. doi: 10.2147/VHRM.S23491. Epub 2012 Feb 27. Review.

13.

Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.

Showkathali R, Davies JR, Parker M, Taggu W, Tang KH, Clesham GJ, Gamma RA, Sayer JW, Aggarwal RK, Kelly PA.

Cardiovasc Revasc Med. 2013 Sep-Oct;14(5):289-93. doi: 10.1016/j.carrev.2013.07.006. Epub 2013 Aug 22.

PMID:
23972537
14.

Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.

Ndrepepa G, Neumann FJ, Deliargyris EN, Mehran R, Mehilli J, Ferenc M, Schulz S, Schömig A, Kastrati A, Stone GW.

Circ Cardiovasc Interv. 2012 Oct;5(5):705-12. doi: 10.1161/CIRCINTERVENTIONS.112.972869. Epub 2012 Oct 9.

15.

Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.

Stone GW, Mehran R, Goldstein P, Witzenbichler B, Van't Hof A, Guagliumi G, Hamm CW, Généreux P, Clemmensen P, Pocock SJ, Gersh BJ, Bernstein D, Deliargyris EN, Steg PG.

J Am Coll Cardiol. 2015 Jan 6;65(1):27-38. doi: 10.1016/j.jacc.2014.10.029.

16.

Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.

Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, Chen S, Jiang T, Yang P, Chen J, Jiang D, Jing Q, Liang Z, Liu H, Zhao X, Li J, Li Y, Xu B, Stone GW; BRIGHT Investigators.

JAMA. 2015 Apr 7;313(13):1336-46. doi: 10.1001/jama.2015.2323.

PMID:
25775052
17.

Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

Lincoff AM, Steinhubl SR, Manoukian SV, Chew D, Pollack CV Jr, Feit F, Ware JH, Bertrand ME, Ohman EM, Desmet W, Cox DA, Mehran R, Stone GW; Acute Catheterization and Urgent Intervention Triage strategY of Trial Investigators.

JACC Cardiovasc Interv. 2008 Dec;1(6):639-48. doi: 10.1016/j.jcin.2008.10.004.

18.

Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Stone GW.

J Am Coll Cardiol. 2008 Sep 2;52(10):807-14. doi: 10.1016/j.jacc.2008.05.036.

19.

Benefit of bivalirudin versus heparin after transradial and transfemoral percutaneous coronary intervention.

MacHaalany J, Abdelaal E, Bataille Y, Plourde G, Duranleau-Gagnon P, Larose É, Déry JP, Barbeau G, Rinfret S, Rodés-Cabau J, De Larochellière R, Roy L, Costerousse O, Bertrand OF.

Am J Cardiol. 2012 Dec 15;110(12):1742-8. doi: 10.1016/j.amjcard.2012.07.043. Epub 2012 Sep 14.

PMID:
22980964
20.

Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study.

Hamon M, Rao SV, Steg G, Valgimigli M, Verheugt F, Marso S, Gershlick A, Wang Y, Deliargyris E.

EuroIntervention. 2012 Aug;8(4):486-92. doi: 10.4244/EIJV8I4A76.

Supplemental Content

Support Center